Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture Atomoxetine capsules that are used for the treatment of attention-deficit hyperactivity disorder (ADHD).
"Atomoxetine capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg will be launched immediately," the company said. "The product is AB rated that meets necessary bioequivalence standards, the generic equivalent of Eli Lilly and its Strattera capsules."
ADHD is a neurobiological disorder that affects normal behaviour and impairs the ability to concentrate. Though the ADHD symptoms begin in childhood, it can continue through adolescence and adulthood.
The generic Atomoxetine is manufactured by other companies such as Sun Pharma, Intas and Torrent having brand names Attentrol, Axepta and Tomoxetin, respectively. The type of drug comprises of both tablets and capsules.
Atomoxetine has an estimated market size of $1.1 billion for the twelve months ending March 2017, according to global information services company IMS Health.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in